PD-1/PD-L1-IN-33

• UNSPSC Description:

  PD-1/PD-L1-IN-33 (Compound N11) is a PD-1/PD-L1 inhibitor. PD-1/PD-L1-IN-33 inhibits PD-1 and PD-L1 interaction with an IC50: 6.3 nM. PD-1/PD-L1-IN-33 promotes T-cell proliferation, activation, and infiltration into tumor spheres. PD-1/PD-L1-IN-33 has immunomodulatory and anticancer activity[1].

• Target Antigen:

  PD-1/PD-L1

• Type:

  Reference compound

• Related Pathways:

  Immunology/Inflammation

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/pd-1-pd-l1-in-33.html

• Solubility:

  DMSO : 100 mg/mL (ultrasonic;warming;heat to 80°C)

• Smiles:

  CC(C)(CO)NCC1=CC2=C(N=C1)C(N3C4=C(CC3)C(C5=CC=CC=C5)=CC=C4)=NC=N2

• Molecular Weight:

  425.53

• References & Citations:

  [1]Yangyang Meng, et al. Novel 4-Arylindolines Containing a Pyrido[3,2-d]pyrimidine Moiety as the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction Inhibitors for Tumor Immunotherapy. J. Med. Chem. 2023.

• Shipping Conditions:

  Room Temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  2975602-78-7